Rhythm Pharmaceuticals logo

Rhythm Pharmaceuticals

RYTM | NASDAQ
Chart Builder DCF Calculator
$107.48
-$7.54 (-6.56%)
At close: Nov 16, 2026, 4:00 PM ET
$107.48
$0.00 (0.00%)
After-hours: Nov 16, 2026, 7:30 PM ET
-6.56%

Rating

Updated: Nov 16, 2026
45.9
Fundamentals Average
Market Sentiment Neutral
Moat Narrow
Sector Rank #373/1021 (Top 37%)

Key Statistics

Market Data

Market Cap $7.45B
1D Range
107.22 115.07
52W Range
75.82 117.62

Valuation (TTM)

PE -37.06
PB 36.97
EV/EBITDA -41.18

Valuation (NTM)

Forward PE 2,084.70
Forward PEG -0.67
Price Target $154.00
Loading financial charts...

Profile

Rhythm Pharmaceuticals, Inc. is a biopharmaceutical company with commercial products, dedicated to the discovery, development, and market launch of therapies addressing rare genetic conditions that ca...

Sector Healthcare
Industry Biotechnology
Employees 414
IPO Date Oct 9, 2017
Fiscal Year January - December

Latest News

Rhythm Pharmaceuticals Announces Presentation of New Data at ObesityWeek® 2026

11 hours ago · globenewswire.com

Rhythm Pharmaceuticals Announces Presentation of New Data at ObesityWeek® 2026
Rhythm Pharmaceuticals: Bull Case Intact, But The Market Is Pricing In A Lot

6 days ago · seekingalpha.com

Rhythm Pharmaceuticals: Bull Case Intact, But The Market Is Pricing In A Lot
Rhythm Pharmaceuticals, Inc. (RYTM) Q3 2026 Earnings Call Transcript

14 days ago · seekingalpha.com

Rhythm Pharmaceuticals, Inc. (RYTM) Q3 2026 Earnings Call Transcript
Rhythm Pharmaceuticals Q3 Earnings Call Highlights

14 days ago · marketbeat.com

Rhythm Pharmaceuticals Q3 Earnings Call Highlights
Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q3 Loss, Beats Revenue Estimates

14 days ago · zacks.com

Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q3 Loss, Beats Revenue Estimates
Rhythm Pharmaceuticals Reports Third Quarter 2026 Financial Results and Business Update

14 days ago · globenewswire.com

Rhythm Pharmaceuticals Reports Third Quarter 2026 Financial Results and Business Update
Rhythm Pharmaceuticals and LG Chem Enter into Amendment to Bivamelagon Exclusive License Agreement

14 days ago · globenewswire.com

Rhythm Pharmaceuticals and LG Chem Enter into Amendment to Bivamelagon Exclusive License Agreement
Rhythm Pharmaceuticals, Inc. (RYTM) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release

21 days ago · zacks.com

Rhythm Pharmaceuticals, Inc. (RYTM) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
Rhythm Pharmaceuticals to Report Third Quarter 2026 Financial Results on Tuesday, November 3, 2026

27 days ago · globenewswire.com

Rhythm Pharmaceuticals to Report Third Quarter 2026 Financial Results on Tuesday, November 3, 2026
Rhythm Pharmaceuticals (RYTM) Upgraded to Buy: Here's What You Should Know

1 month ago · zacks.com

Rhythm Pharmaceuticals (RYTM) Upgraded to Buy: Here's What You Should Know

Earnings

Latest Earnings
Nov 3, 2026
EPS
-$0.61
Beat +14.05%
REV
$92.13M
Beat +7.67%
Next Earnings
Feb 25, 2027
EPS Est
Pro
Rev Est
Pro
Earnings Details ➞

Analyst Summary

# of Analysts
13
Consensus
Buy
Price Target
$154.00
Upside
+43.28%
Buy (13)
Hold (0)
Sell (0)
Analyst Details ➞

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.